A Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of 700 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients With Diabetic Macular Edema
Phase of Trial: Phase III
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Dexamethasone (Primary) ; Ranibizumab
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Sponsors Allergan
- 02 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jun 2013 New source identified and integrated (United Kingdom Clinical Research Network, 12137).
- 03 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.